Drugs / CART-138 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01886976 | Jun 2013 → Jun 2016 | plasma cell myeloma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-138 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01886976 ↗ |
| Action | Deplete | “For patients with stored or accessible myeloma cells, determine myeloma cell killing by CART-138 cells in vitro.” NCT01886976 ↗ |
| Modality | Cell therapy | “genetically engineered lymphocyte therapy” NCT01886976 ↗ |